The pharmacokinetics of intratumorally administered therapeutics is not yet well understood and characterized, and these studies shed new light on how soluble TRAIL responds within the compact tumor environment.[35] We further explore the mechanoresponse of PCa cells to FUS‐mediated therapy to provide methods that can overcome drug resistance in cancer and enhance therapeutic efficacy. This evidence concerns the gene TNFSF10 and cancer.